|Canaccord Genuity||John Newman|
|Echelon Wealth Partners||Douglas Loe|
|Ladenburg Thalmann||Wangzhi Li|
|Paradigm Capital||Rahul Sarugaser|
|RBC Capital Markets||Douglas Miehm|
|Roth Capital Partners||Jerry Isaacson|
Oncolytics Biotech, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Oncolytics Biotech, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Oncolytics Biotech, Inc. or its management. Oncolytics Biotech, Inc. does not by its reference above or distribution, imply its endorsement of or concurrence with such information, conclusions or recommendations.